

Today's comment(s)

[SOBI \(SELL, Fair Value SEK90\)](#)

Q3 16 above expectations, but FY guidance raised in line with consensus; a slight miss in Haemophilia

Q3 16 results are admittedly above estimates (EBITA: SEK282m vs BG: SEK215m and CS: SEK186m). Plus, the EBITA guidance for the whole year has been increased... But we cannot ignore that 1/ the new targets are in line with consensus' estimates before this publication; 2/ haemophilia products (the main drivers of the valuation in our view) fell short of expectations. Overall, this does not change our bearish call that the overall consensus for the Haemophilia franchise is likely to be adjusted downward.

[Melexis \(SELL, Fair Value EUR48\)](#)

Q3 results and conference call confirmed our view

Only few more information have been given yesterday during the conference call. Melexis confirmed that R&D investments will increase from Q4 and also in FY17 adding pressure on operating margin as we expected. Overall, our investment case does not change following this call, we are convinced that, despite the company continues to deliver, Melexis valuation metrics are too high. We reiterate our Sell recommendation and our FV of EUR48.

[Grandvision \(BUY, Fair Value EUR28\)](#)

Lower-than-expected Q3 results but FY outlook confirmed

This morning GrandVision released Q3 sales up 2.2% to EUR825m, shy of the CS at EUR853m, mostly because of a weaker-than-expected comparable growth (+0.4% vs. CS: +3.5%) after +2.3% in H1. Following this weak top line performance, the adj. EBITDA reached EUR139m (CS: EUR151m), representing a 70bp-margin decline to 16.8%. Despite this disappointing quarter, GrandVision is confident to achieve this year its MT targets ("at least +5% FX-n" and high single-digit adj. EBITDA growth).

[STMicroelectronics \(NEUTRAL, Fair Value EUR6.5\)](#)

Q3 adjusted results a penny above expectations, while Q4 outlook is supportive

Q3 sales came out at USD1.797bn, up 5.5% seq., in line with company guidance and broadly in line with expectations. The gross margin improved from 33.9% in Q2 to 35.5% in Q3, yielding Adjusted EBIT of USD119m and adjusted EPS of USD0.11, i.e. a penny above expectations for Adjusted EPS of 0.10 (BG ests. USD0.08). In addition, the group continues to enjoy healthy demand in the market it serves and Q4 2016 revenue guidance is ahead of the street's estimates with revenues set to grow 3.2% (+/- 350bp) sequentially, i.e. sales slightly above USD1.850bn, while current forecasts were for USD1.802bn (BG ests. USD1,868m) and GM is expected to be close to 37.0% vs. cons. at 36.1%.

[Suez \(BUY-Top Picks, Fair Value EUR17.5\)](#)

9M-16 results – first take: half-way to the full-year EBIT guidance

Suez unveiled its 9M-16 results this morning. EBITDA and EBIT were EUR1,957m and EUR932m respectively, both above consensus' expectations. EUR40m of additional savings from 2017 have been announced with the company aiming to speed-up its transformation plan, as expected. Suez confirmed its FY16 guidance thanks to a solid performance in Q3-16 (+5.7% organic growth). We estimated a 5.1%+ organic growth needs to be reached in Q4-16 to achieve the 2%+ guidance level. Positive. Buy rating confirmed and FV unchanged at EUR17.5. Conference call @ 8:30am.

[Innate Pharma \(BUY, Fair Value EUR20 vs. EUR18\)](#)

IPH4102: preliminary... but very promising efficacy data; FV raised

We were very positively surprised by IPH4102's preliminary efficacy data in CTCL (ORR: 38%) especially since 1/ most patients suffered from Sezary Syndromes (and thus with the poorer prognosis), and were heavily pre-treated; 2/ the dose escalation part is far from finished. As they already compare (very) favourably with approved products or candidates under development, we have decided to include this early-stage compound in our SOTP... Hence a new FV of EUR20 (vs EUR18).

[Ingenico Group \(BUY, Fair Value EUR112\)](#)

Good resilience in Q3 and momentum not very strong until H1 2017, but valuation too low

ING posted a better-than expected set of Q3 sales (+7% lfl vs. cons. +3% and BG est. +2.5%), reflecting good resilience. Situation is mixed for payment terminals (strong in EMEA and APAC i.e. 85% of sales, but difficult and with high comps in the US and Brazil i.e. 15% of sales) and very good for payment services (both for in-store and ePayments). The group maintained its 2016 guidance, namely $\geq 7\%$ in lfl sales growth and $\geq 20\%$ in EBITDA margin. Even if the momentum is not very attractive until H1 2017, the EBITDA margin hypothesis we have to put into a reverse DCF to justify the current price is excessively low and illogical. Buy recommendation and FV of EUR112 maintained.

[BIC \(NEUTRAL, Fair Value EUR124 vs. EUR123\)](#)

Ongoing market share gains in a more fiercely competitive environment
Although BIC is on track to reach its sales guidance ("mid single-digit growth"), it is striking to note the persistent outperformance of North America in Consumer Business (+1.8% LFL in 9M) vs. Europe (+7.7% LFL) and even Developing Markets (+7% LFL). Besides an unhelpful US final demand, BIC also reckoned that the competitive environment became harsher, especially in Shavers. We make minor adjustments within our FY16 assumptions leading to our new FV of EUR124 vs. EUR123, but we confirm our Neutral recommendation due to the stretched valuation.

[Altran Technologies \(BUY, Fair Value EUR15\)](#)

Q3 2016 sales roughly in line with expectations; outlook reiterated

This morning, Altran reported Q3 2016 revenues 1% below our forecast and consensus, with growth momentum negatively impacted by calendar effects (1.4ppt headwind). Unsurprisingly, management considers 2016 will be another year of profitable growth. We expect the share price to show a slightly negative reaction in the short-term, given the slowdown of "economic growth" (+5.1% in Q3 vs. 6% in H1), which stems from a contextual business transition in Italy.

Brief comments

[Korian \(NEUTRAL, Fair Value EUR28\)](#)

Conference call Q3 revenue: Better lfl growth than expected. FY guidance confirmed.

[Scor \(BUY, Fair Value EUR35\)](#)

Very solid Q3 numbers

[Rémy Cointreau \(BUY-Top Picks, Fair Value EUR84\)](#)

Plan to acquire Domaine des Hautes Glaces

Latest Recommendation Changes

DIA : We wish management could maintain the good momentum initiated in Q2

SOBI : Haemophilia: « Stemming the bleed »

TEMENOS GROUP : Large deal with a major European bank

InterContinental Hotels : Top picks: ...and the winner is Melia.

PLASTIC OMNIUM : Innovation: the only way to stand out!

HELLA : Innovation: the only way to stand out!

FAURECIA : Innovation: the only way to stand out!

Latest Fair value changes

INNATE PHARMA : IPH4102: preliminary... but very promising efficacy data; FV raised

DIA : We wish management could maintain the good momentum initiated in Q2

GROUPE SEB : And the beat goes on!

TOD'S GROUP : Q3 sales declined 4.8% at same forex

SWORD GROUP : Q3 2016 results still outperform full-year targets; FY16 guidance likely to be exceeded

ams : Strong Q3, warning on Q4 and an acquisition likely not to be accretive before 2018e

Stocks Factor to watch today on Mid & Small :

ALTRAN TECHNOLOGIES: 3Q REV EU500.9M ; EXPECTS 2016 TO BE ANOTHER YR OF PROFITABLE GROWTH

GRANDVISION: 3Q REV UP 4.9%, 9M REV GROWTH 6.1% AT CONSTANT FX; 9M OPER. PROFIT EU289M VS EU285M; CONFIDENT IN ACHIEVING ITS MEDIUM TERM OBJECTIVES OF FY REVENUE GROWTH OF AT LEAST 5%

INGENICO: COMP. 3Q REV. ROSE BY 7% (EU570M VS EST. EU549 M); CONFIRMS FY GOALS FOR EBITDA MARGIN, ORGANIC GROWTH

INNATE PHARMA: ENCOURAGING INITIAL RESULTS FOR IPH4102 (SHOWS GOOD SAFETY PROFILE)

RÉMY COINTREAU: IN TALKS WITH DOMAINE DES HAUTES GLACES DISTILLERY WITH A VIEW TO ACQUIRING ITS ENTIRE SHARE CAPITAL; PURCHASE CONTRACT MAY BE SIGNED BY END OF '16

SCOR: 3Q P&C COMBINED RATIO 91.4%; 3Q NET INCOME EU163M, 9-MONTH NET EU438M

SOBI : 3Q REV. SK1.17B, EST. SK1.13B; 3Q EBITA SK282M, EST. SK175.1M; RAISES 2016 GUIDANCE; SEES 2016 REVENUES OF SK5.13B TO SK5.20B; SEES 2016 GROSS MARGIN 70% VS PREVIOUS GUIDANCE 68-70%

STMICROELECTRONICS 3Q REV. \$1.8B; EST. \$1.8B; 3Q GROSS MARGIN 35.8% SEES 4Q GROSS MARGIN ABOUT 37.0%; EXPECTS 2016 PROFITABILITY TO IMPROVE

Rating & TP Changes



+INNATE: FV RAISED TO EU20 VS 18 AT BRYAN GARNIER

+ADOCIA: RATED NEW BUY AT KEPLER CHEUVREUX; PT EU 91

Technical analysis

	Last close	%var 1D	% var 31/12/15
FRANCE CAC MID & SMALL	11201.36	-0.48%	+1.34%
STOXX EUROPE TM MID	502.205	-0.50%	-6.69%

*BG Coverage

Highest YTD : ABC ARBITRAGE (BITI.PA), ARGAN (ARGAN.PA), CHARGEURS (CRIP.PA), GEVELOT (ALGEV.PA), GPE GROUPE PIZZORNO (GPEP.PA), **IMERYS*** (IMTP.PA), LANSON-BCC (LAN.PA), MANUTAN INTL. (MATP.PA), POL-ROGER ET COMPAGNIE LIMITED DATA (PRCH.PA), **SEB*** (SEBF.PA), SII (IISP.PA), THEOLIA (FTRN.PA)

Lowest YTD : **ABLYNX*** (ABLX.BR), AMATHEON AGRI (MLAAH.PA), **BONE THERAPEUTIC*** (BOTHE.BR), **CELYAD*** (CYAD.BR), ETAM DEVELOPEMENT (TAM.PA), GEOX (GEO.MI), GFI INFORMATIQUE (GFIP.PA), ONXEO (C4X.PA), SEQUANA (SEQ.PA), SMA SOLAR TECH. (XET) (S92G.DE), TXCELL (TXCL.PA)

Excess volume/1D : 1000MERCIS (ALMIL.PA), **ABLYNX*** (ABLX.BR), APRIL (APRL.PA), ATEME (ATEME.PA), **BIOMERIEUX*** (BIOX.PA), **BOSS (HUGO) (XET)*** (BOSSn.DE), CEGID GROUP (CEGI.PA), **CELLECTIS*** (ALCLS.PA), **CELYAD*** (CYAD.BR), CRCAM LANGUED CCI (CRLA.PA), CREDIT AGR.TOURAINE (CRTO.PA), **DIALOG SEMICON.*** (DLGS.F), **DISTRIBUIDORA INTNAC.DE ALIMENTACION*** (DIDA.MC), ESI GROUP (ESIG.PA), ETAM DEVELOPEMENT (TAM.PA), EURO RESSOURCES (EURR.PA), GAUMONT (GAUM.PA), GPE

GRUPE PIZZORNO (GPEP.PA), **GRANDVISION*** (GVNV.AS), GRIFOLS CLASS 'B' SHARE (GRLSbn.MC), ICADÉ (ICAD.PA), ID LOGISTICS GROUP (IDLA.PA), IGE + XAO (IGXA.PA), **INNATE PHARMA*** (IPH.PA), **IPSEN*** (IPN.PA), IT LINK (ITLI.PA), LANSON-BCC (LAN.PA), LE BELIER (LBEL.PA), LE NOBLE AGE (LNA.PA), LOCINDUS (LOCI.PA), MAISON FRANCE CONFORT (MFCP.PA), **ORPEA*** (ORP.PA), PUMA (XET) (PUMG.DE), **REMY COINTREAU*** (RCOP.PA), **SEB*** (SEBF.PA), SEQUANA (SEQ.PA), SII (IISP.PA), SMA SOLAR TECH. (XET) (S92G.DE), SOFRAGI (SRAG.PA), STRATEC BIOMEDICAL (XET) (SBSG.DE), **SWORD GROUP*** (SWOR.PA), THEOLIA (FTRN.PA), U10 (L3C.PA), **VOLTALIA*** (VLTA.PA), **WIRECARD (XET)*** (WDIG.DE)

⁽¹⁾ Compare the previous day trading volume to last month average volume traded

Calendar

Date	Company name	type
27/10/16	• SCOR SE(SCR FP)	Earnings result : 07:30
	• Altran Technologies SA(ALT FP)	
	• SCOR SE(SCR FP)	Earnings result : 09:30
	• STMicroelectronics NV(STM IM)	Earnings result : Bef-mkt
	• Alten SA(ATE FP)	
	• Axway Software SA(AXW FP)	Earnings result : Aft-mkt
	• Alten SA(ATE FP)	Earnings result :
	• Voltalia SA(VLTA FP)	
	• GrandVision NV(GVNV NA)	
	• Gemalto NV(GTO NA)	Earnings result :
28/10/16	• Software AG(SOW GR)	Shareholders meeting
01/11/16	• HUGO BOSS AG(BOSS GR)	Earnings result : 07:30
02/11/16	• HUGO BOSS AG(BOSS GR)	Earnings result : 14:00
	• QIAGEN NV(QGEN US)	Earnings result : 21:00
03/11/16	• Sopra Steria Group(SOP FP)	Earnings result :
	• Dialog Semiconductor PLC(DLG GR)	Earnings result : 10:30
	• Vicat SA(VCT FP)	Earnings result :
	• Ubisoft Entertainment SA(UBI FP)	Earnings result :
	• Dialog Semiconductor PLC(DLG GR)	Earnings result :
	• Orpea(ORP FP)	
	• Innate Pharma SA(IPH FP)	
	• DBV Technologies SA(DBV FP)	Earnings result :
	• Coface SA(COFA FP)	Earnings result :